BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 25677447)

  • 1. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
    Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
    Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
    Dogan M; Karabulut HG; Tukun A; Demirkazik A; Utkan G; Yalcin B; Dincol D; Akbulut H; Icli F
    Asian Pac J Cancer Prev; 2012; 13(4):1553-6. PubMed ID: 22799365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
    Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
    Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
    Afzal S; Gusella M; Jensen SA; Vainer B; Vogel U; Andersen JT; Brødbæk K; Petersen M; Jimenez-Solem E; Adleff V; Budai B; Hitre E; Láng I; Orosz E; Bertolaso L; Barile C; Padrini R; Kralovánszky J; Pasini F; Poulsen HE
    Pharmacogenomics; 2011 Sep; 12(9):1257-67. PubMed ID: 21919605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
    Gonzalez-Haba E; García MI; Cortejoso L; López-Lillo C; Barrueco N; García-Alfonso P; Alvarez S; Jiménez JL; Martín ML; Muñóz-Fernández MA; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2010 Dec; 11(12):1715-23. PubMed ID: 21142915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
    Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of capecitabine in advanced breast cancer patients.
    Largillier R; Etienne-Grimaldi MC; Formento JL; Ciccolini J; Nebbia JF; Ginot A; Francoual M; Renée N; Ferrero JM; Foa C; Namer M; Lacarelle B; Milano G
    Clin Cancer Res; 2006 Sep; 12(18):5496-502. PubMed ID: 17000685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.